1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Legislation

Industry Pushes For Revised PFAS Definition In California Bill Seeking Cosmetic Ban

 
• By Lauren Nardella

The Personal Care Products Council and other industry groups suggest they will support AB 2771 if amendments are made to promote international harmonization, among other changes. Already they advocated successfully for the bill’s scope to be limited to intentionally added PFAS, not “the mere presence of trace levels of fluorine in the product.”

• Source: Shutterstock

The cosmetics industry is urging California lawmakers to harmonize a bill’s definitions of perfluoroalkyl and polyfluoroalkyl substances with international guidelines. They suggest that if amendments are made they will support the measure that would prohibit the sale or manufacture of cosmetic products in the state that contain PFAS.

AB 2771 was introduced in February and if passed would go into effect starting in 2025. It builds on the state’s 2020 Toxic-Free Cosmetics Act, which prohibits the intentional use of listed ingredients of concern in cosmetic products, including 13 PFAS, beginning on 1 January 2025

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

No Longer Voluntary, MoCRA Drives Drastic Increase In Registered Companies, Products

 
• By Lauren Nardella

Preliminary registration data released by FDA offers a first glimpse of the Modernization of Cosmetics Regulation Act’s impact on information the agency has at hand.

WA Regulators Open Rulemaking On Cosmetic Lead Limits; Provide Safe Harbor Under TFCA

 
• By Eileen Francis

The Washington State Department of Ecology publishes ‘Interim Policy on Lead in Cosmetics’ which provides safe harbor options for cosmetic products struggling with the 1ppm limit under the state’s Toxic Free Cosmetics Act, while the department gathers information under a newly opened rulemaking to ‘identify a feasible approach to regulating lead in cosmetic products.’

WA State Regulators Haven’t Softened Stance On Preservatives, Provided Clarity On Penalties As TFCA Effective Date Nears

 
• By Eileen Francis

The Washington Department of Ecology hasn’t backed down on its targeting of formaldehyde-releasing preservatives under the state’s Toxic-Free Cosmetics Act, as industry still awaits a draft final rule. In a recent webinar, attorney Angela Deisch of Amin Wasserman Gurnani, LLP said the department has also not provided clarity on penalties under the law, which goes into effect 1 January.

Industry Support Key To US FDA’s Prospects Under Trump – Califf

 
• By Sue Sutter

The FDA's current leader, whose term will end with Donald Trump’s second inauguration, also described three qualities the agency’s next commissioner will need to succeed, including "believing that there is such a thing as expertise."

More from Policy & Regulation

US Fragrance Firms Should Identify Domestic, Non-Tariff Sources Now – Fragrance House CEO

Firms in the US facing tariff costs should identify US-based, non-tariff sources and lobby local government officials and DC when foreign-sourced ingredients cannot be substituted in the US.

Cosmetics Consortium Shares Studies With FDA To Build Confidence In Animal Testing Alternatives

 
• By Lauren Nardella

By guiding regulators through case studies and mock dossier examples of how to utilize new approach methodologies, the International Collaboration on Cosmetics Safety hopes to counter hesitations in replacing animal tests.

Stakeholders Hope US FDA’s Proposed Animal Test Phase-Out For Drugs Will Extend To OTCs, Cosmetics

 
• By Eileen Francis and Lauren Nardella

The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.